Steady‐State Pharmacokinetics of Citalopram in Young and Elderly Subjects

Abstract

The pharmacokinetics and tolerability of citalopram in elderly subjects are similar to those observed in younger subjects. The slight differences observed in the elderly likely reflect declining liver and kidney function.

Selective Serotonin Reuptake Inhibitor and Substance P Antagonist Enhancement of Natural Killer Cell Innate Immunity in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

“…At this concentration (10 −6 mol/L), each pharmacologic agent (Atlanta Biologicals, Norcross, Georgia) was added to a separate aliquot of 4 × 10 −6 PBMCs/4 mL RPMI 1640 plus 10% fetal bovine serum (FBS). These ex vivo concentrations are consistent with steady state plasma concentrations in individuals taking citalopram and RU486, the two licensed drugs (57)(58)(59)(60). The next morning following the 18 hours incubation and within our 30-hour window, the natural killer cell assay was performed.…”

Aging Biology and Geriatric Clinical Pharmacology

“…The clearance of drugs that undergo phase II metabolism [e.g., mizolastine (Lebrun-Vignes et al, 2001)] is unchanged in old age, whereas drugs that undergo phase I metabolism [e.g., ropinirole (Kaye and Nicholls, 2000), citalopram (Gutierrez and Abramowitz, 2000), rabeprazole (Swan et al, 1999), argatroban (Swan and Hursting, 2000)] have reduced clearance in older people. On the other hand, a review of pharmacokinetics found that aging in volunteers and subjects with rheumatoid arthritis was not associated with any significant change in cyclosporin pharmacokinetics; although, clearance was lower in older renal transplant recipients (Kovarik and Koelle, 1999).…”

Influence of Concomitant Medications on the Total Clearance and the Risk for Supra-therapeutic Plasma Concentrations of Citalopram. A Population-Based Cohort Study

“…For the Cl t of citalopram a range of 367-545 mL/min (arithmetic mean ± standard deviation) has been estimated during pre-clinical trials [15][16][17] which can be used to calculate a range within which 68 % of all drug plasma concentrations are expected in a "normal" patient under medication with a given dose of the drug [13]: c max = D/Cl t max ; c min = D/Cl t min. The term "normal patient" refers to the study population of the phase II clinical trials in which pharmacokinetic parameters of a drug are usually estimated.…”